SCHEMBL2367968

SCHEMBL2367968

CC(C)(C)COc1c(C=Cc2nc3sccn3c2C(=O)NCc2cccc(C(F)(F)F)c2)cccc1OC(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
PLA2G1B P04054 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
GAA P10253 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ATG4B Q9Y4P1 1/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
CCR1 P32246 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2367966 1.00 HRH4 (0.36) HRH4NPC1RAB9AMEN1KMT2A
SCHEMBL13287368 0.89 HRH4 (0.36) HRH4NPC1RAB9AMEN1KMT2A
SCHEMBL2824070 0.89 EPAS1 (0.42) NPC1MEN1KMT2A
SCHEMBL2368441 0.88 HTT (0.31)
SCHEMBL2368436 0.88 HTT (0.31)
SCHEMBL2825013 0.84 ALDH1A1 (0.36) RAB9AMEN1KMT2AGAATDP1
SCHEMBL2825016 0.84 ALDH1A1 (0.36) RAB9AMEN1KMT2AGAATDP1
SCHEMBL2827361 0.84 NPC1 (0.30) NPC1RAB9AMEN1KMT2A
SCHEMBL2827365 0.84 NPC1 (0.30) NPC1RAB9AMEN1KMT2A
SCHEMBL2829848 0.84 HTT (0.34) NPC1RAB9ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318928-B2 Fused imidazole carboxamides as TRPV3 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2012-11-27 US claimed
EP-2367825-A1 Fused imidazole carboxamides as trpv3 modulators Glenmark Pharmaceuticals S.A. (CH) 2011-09-28 EP claimed
WO-2010070452-A1 FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-06-24 WO claimed
US-20100152192-A1 FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A (CH) 2010-06-17 US claimed
US-8318928-B2 Fused imidazole carboxamides as TRPV3 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2012-11-27 US disclosed
EP-2367825-A1 Fused imidazole carboxamides as trpv3 modulators Glenmark Pharmaceuticals S.A. (CH) 2011-09-28 EP disclosed
WO-2010070452-A1 FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-06-24 WO disclosed
US-20100152192-A1 FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A (CH) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152192-A1 FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS TRPV3, TRPV1, TRPV2 HRH4 98/4885NPC1 744/4885RAB9A 2769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.